Definitive Contract HHSN261201300087C
Award Date 9/20/13
Potential Completion Date 9/19/15
Potential Value $1.5M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Award Fee
Place of Performance
Nashville, TN 37217, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- <p>The U.S. National Cancer Institute awarded a $200,000.00 firm fixed-price definitive contract to Insight Genetics, Inc., a small business, on September 30, 2010. The contract has a completion date of May 3, 2011 and was set aside for small businesses. The contract is for research and development services related to the National Cancer Institute's work, performed in Nashville, Tennessee.</p>
- This is a $1,698,988.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services (HHS), to Insight Genetics, Inc., a small business. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a total small business set-aside designation. The contract was awarded on September 20, 2012 and has an ultimate completion date of August 16, 2015. This contract award is not associated...
- <p>This is a $1,494,102.45 cost-plus-fixed-fee contract awarded by the National Cancer Institute (a civilian agency) to Insight Genetics, Inc., a small business. The contract is for the development of a companion diagnostic for ALK mutations. It was awarded on September 28, 2012 and has a final completion date of February 5, 2015. This appears to be a stand-alone contract and not part of a larger contract vehicle.</p>
- The National Cancer Institute awarded a $224,997.00 firm fixed-price definitive contract to Paganini Biopharma, Inc. for research and development in biomedical basic research. The contract has a performance period ending on September 17, 2015 and was awarded on September 18, 2014. This contract was not set aside for any specific business type. The National Cancer Institute is a civilian agency within the U.S. Department of Health and Human Services that conducts and supports cancer research.
- The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, has awarded a $19,240 firm fixed price delivery order contract to Illumina, Inc. of San Diego, California. The contract is for supplies to support the agency's biomedical research mission. Illumina will provide products under the contract through December 2023 to assist NCI in advancing its goals of understanding, detecting and treating cancer through research. No...
- This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency, to Insight Genetics, Inc., a small business. The $193,637 firm-fixed-price contract is for the development of a clinical diagnostic assay to detect ALK inhibitor resistance mutations under the SBIR (Small Business Innovation Research) program. The contract has a period of performance through July 31, 2012 and was awarded on September 30, 2011. As an SBIR award, this contract was set aside for...
- The National Cancer Institute (NCI) awarded a $142,009.29 firm fixed-price purchase order contract to Fundacio Centre De Regulacio Genomica, a non-profit biomedical research institute, to perform targeted gene sequencing on samples collected by NCI's Division of Cancer Epidemiology and Genetics. This contract, which does not have a set-aside designation, is expected to be completed by June 2023. The contract was awarded in September 2021 under simplified acquisition procedures for commercial...
- <p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
- The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $228,009.60 firm fixed price delivery order contract to Illumina, Inc. of San Diego, California. The contract is for reagents and consumables to be provided between December 19, 2023 and January 18, 2024 at Illumina's facility in San Diego. No additional details were provided on the original solicitation or associated contract vehicles. The award does...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute (HHS-NIH-NCI) awarded a $58,814.72 firm fixed price delivery order contract to Illumina, Inc. of San Diego, California. The contract is for reagents and consumables to support the NCI's biomedical research efforts. As the prime contractor, Illumina will provide the requested products for use at its place of performance in San Diego through September 2023. No set aside designation or subcontractors...